"It's as if there is a new medicine coming out in the market, there would be some buyers. Some other people want the medicine to be tested before they buy. That's the case here."
-- Aaron So, a credit structurer at BNP Paribas in Hong Kong, on why some firms have been hesitant to begin trading onshore credit derivatives.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts
